OraSure Technologies (NASDAQ:OSUR) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.03, Briefing.com reports. The company had revenue of $43.60 million during the quarter, compared to the consensus estimate of $42.24 million. OraSure Technologies had a return on equity of 6.58% and a net margin of 9.28%. OraSure Technologies’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.09 earnings per share. OraSure Technologies updated its Q3 guidance to $0.10-0.12 EPS.
Shares of NASDAQ:OSUR traded up $0.10 during midday trading on Friday, reaching $16.76. The company’s stock had a trading volume of 399,200 shares, compared to its average volume of 565,234. The company has a market cap of $1.02 billion, a P/E ratio of 32.86, a P/E/G ratio of 4.19 and a beta of 1.56. OraSure Technologies has a 1 year low of $12.86 and a 1 year high of $23.01.
A number of equities research analysts have recently commented on OSUR shares. Zacks Investment Research downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, April 18th. Stephens downgraded OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research report on Monday, July 16th. ValuEngine raised OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Friday, July 6th. Finally, TheStreet downgraded OraSure Technologies from a “b” rating to a “c+” rating in a research report on Wednesday, May 2nd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $21.33.
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.